JPS61191609A - 徐放性製剤 - Google Patents
徐放性製剤Info
- Publication number
- JPS61191609A JPS61191609A JP3233085A JP3233085A JPS61191609A JP S61191609 A JPS61191609 A JP S61191609A JP 3233085 A JP3233085 A JP 3233085A JP 3233085 A JP3233085 A JP 3233085A JP S61191609 A JPS61191609 A JP S61191609A
- Authority
- JP
- Japan
- Prior art keywords
- pva
- phase
- active substance
- concentration
- pharmacologically active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title abstract description 8
- 230000003578 releasing effect Effects 0.000 title abstract 5
- 239000004372 Polyvinyl alcohol Substances 0.000 claims abstract description 74
- 229920002451 polyvinyl alcohol Polymers 0.000 claims abstract description 74
- 239000013543 active substance Substances 0.000 claims abstract description 24
- 230000008014 freezing Effects 0.000 claims abstract description 19
- 238000007710 freezing Methods 0.000 claims abstract description 19
- 229920000642 polymer Polymers 0.000 claims abstract description 15
- 238000013268 sustained release Methods 0.000 claims description 10
- 239000012730 sustained-release form Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 5
- 239000011148 porous material Substances 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 abstract description 27
- 239000000017 hydrogel Substances 0.000 abstract description 20
- 238000006116 polymerization reaction Methods 0.000 abstract description 8
- 238000002425 crystallisation Methods 0.000 abstract description 7
- 230000008025 crystallization Effects 0.000 abstract description 7
- 238000007127 saponification reaction Methods 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 5
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 239000000829 suppository Substances 0.000 abstract description 2
- 239000006190 sub-lingual tablet Substances 0.000 abstract 1
- 229940098466 sublingual tablet Drugs 0.000 abstract 1
- 239000000499 gel Substances 0.000 description 55
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 239000003405 delayed action preparation Substances 0.000 description 15
- 230000008961 swelling Effects 0.000 description 14
- 238000000034 method Methods 0.000 description 12
- 239000012071 phase Substances 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 10
- 230000007423 decrease Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 239000003431 cross linking reagent Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000010382 chemical cross-linking Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000013081 microcrystal Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 description 1
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- BAPJBEWLBFYGME-UHFFFAOYSA-N acrylic acid methyl ester Natural products COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000009876 antimalignant effect Effects 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920000172 poly(styrenesulfonic acid) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- -1 polyoxyethylene Polymers 0.000 description 1
- 229940005642 polystyrene sulfonic acid Drugs 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000000352 supercritical drying Methods 0.000 description 1
- 238000009864 tensile test Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3233085A JPS61191609A (ja) | 1985-02-20 | 1985-02-20 | 徐放性製剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3233085A JPS61191609A (ja) | 1985-02-20 | 1985-02-20 | 徐放性製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS61191609A true JPS61191609A (ja) | 1986-08-26 |
| JPH0511091B2 JPH0511091B2 (cs) | 1993-02-12 |
Family
ID=12355928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3233085A Granted JPS61191609A (ja) | 1985-02-20 | 1985-02-20 | 徐放性製剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS61191609A (cs) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5346935A (en) * | 1991-05-28 | 1994-09-13 | Takeda Chemical Industries, Ltd. | Hydrogel |
| US6447701B1 (en) | 1997-11-19 | 2002-09-10 | Ingo Heschel | Method for producing porous structures |
| JP2006523613A (ja) * | 2002-12-20 | 2006-10-19 | エスティ．ジェイムス アソシエイト エルエルシー／フェイバー リサーチ シリーズ | 徐放性医薬投与のための被覆粒子 |
| CN111606630A (zh) * | 2020-06-15 | 2020-09-01 | 陕西金磊混凝土有限公司 | 免蒸养高流动性混凝土及其制备方法 |
| WO2021205886A1 (ja) * | 2020-04-10 | 2021-10-14 | 日本酢ビ・ポバール株式会社 | 結合剤 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5956446A (ja) * | 1982-09-24 | 1984-03-31 | Nippon Oil Co Ltd | ポリビニルアルコ−ル凍結ゲルの柔軟性低下法 |
-
1985
- 1985-02-20 JP JP3233085A patent/JPS61191609A/ja active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5956446A (ja) * | 1982-09-24 | 1984-03-31 | Nippon Oil Co Ltd | ポリビニルアルコ−ル凍結ゲルの柔軟性低下法 |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5346935A (en) * | 1991-05-28 | 1994-09-13 | Takeda Chemical Industries, Ltd. | Hydrogel |
| US6447701B1 (en) | 1997-11-19 | 2002-09-10 | Ingo Heschel | Method for producing porous structures |
| JP2006523613A (ja) * | 2002-12-20 | 2006-10-19 | エスティ．ジェイムス アソシエイト エルエルシー／フェイバー リサーチ シリーズ | 徐放性医薬投与のための被覆粒子 |
| JP2012072197A (ja) * | 2002-12-20 | 2012-04-12 | St James Associates Llc Faber Research Series | 徐放性医薬投与のための被覆粒子 |
| WO2021205886A1 (ja) * | 2020-04-10 | 2021-10-14 | 日本酢ビ・ポバール株式会社 | 結合剤 |
| JPWO2021205886A1 (cs) * | 2020-04-10 | 2021-10-14 | ||
| CN115397469A (zh) * | 2020-04-10 | 2022-11-25 | 日本瓦姆&珀巴尔株式会社 | 粘合剂 |
| CN111606630A (zh) * | 2020-06-15 | 2020-09-01 | 陕西金磊混凝土有限公司 | 免蒸养高流动性混凝土及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0511091B2 (cs) | 1993-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5346935A (en) | Hydrogel | |
| Yu et al. | Novel composite double-layered dressing with improved mechanical properties and wound recovery for thermosensitive drug, Lactobacillus brevis | |
| Yoshida et al. | A new temperature-sensitive hydrogel with α-amino acid group as side chain of polymer | |
| JP3134935B2 (ja) | 分岐ポリアンヒドリド | |
| US4164560A (en) | Systems for the controlled release of macromolecules | |
| EP2363104B1 (en) | Hydrogels that undergo volumetric expansion in response to changes in their environment and their methods of manufacture and use | |
| US6030634A (en) | Polymer gel composition and uses therefor | |
| EP1592405B1 (en) | Composition for chemoembolotherapy of solid tumors | |
| Mongia et al. | Mucoadhesive poly (vinyl alcohol) hydrogels produced by freezing/thawing processes: applications in the development of wound healing systems | |
| Sowjanya et al. | Polymers used in the designing of controlled drug delivery system | |
| JPH11510160A (ja) | 重合体薬剤配合物 | |
| JP2006523733A5 (cs) | ||
| CN108310452A (zh) | 一种温敏性葡聚糖基水凝胶及其制备方法 | |
| CN1145480C (zh) | 用于男性的避孕药 | |
| WO1998028364A1 (en) | Novel polymer gel composition and uses therefor | |
| Shi et al. | Sustained release of alginate hydrogel containing antimicrobial peptide Chol-37 (F34-R) in vitro and its effect on wound healing in murine model of Pseudomonas aeruginosa infection | |
| JP3296579B2 (ja) | 成分放出が制御された合成物 | |
| US20220105200A1 (en) | Methods for preventing and treating inflammation and inflammatory disease | |
| JPS61191609A (ja) | 徐放性製剤 | |
| US4781926A (en) | Transdermal therapeutic composition | |
| Çakıcı | Nano TiO2-doped sodium alginate/hydroxypropyl methylcellulose synthesis of bionanocomposite membrane and its use in controlled release of anti-cancer drug 5-fluorouracil | |
| Taşkın Çakıcı | Nano TiO2-doped sodium alginate/hydroxypropyl methylcellulose synthesis of bionanocomposite membrane and its use in controlled release of anti-cancer drug 5-fluorouracil | |
| Bagri et al. | Evaluation of starch based cryogels as potential biomaterials for controlled release of antibiotic drugs | |
| SK1795A3 (en) | Drug delivery device and method of this production | |
| AU2014200734B2 (en) | Hydrogels that undergo volumetric expansion in response to changes in their environment and their methods of manufacture and use |